CA
NZ
UK
AU
IND
US
● Alto Neuroscience shares have risen to $36.25, up 5.75%, onVolumeof about 868,000 shares and relative volume of 1.73, pointing to real institutional interest.
● Arcturus Therapeutics shares have climbed to $14.34, up 6.62%, onVolumeof roughly 2.41 million shares, a touch above its recent norm.
● Aktis Oncology shares have risen to $25.98, up 7.94%, on relativeVolumeof 3.70, nearly four times the stock's typical turnover.
● Yarrow Bioscience shares have jumped to $39.50, up 8.44%, without a specific new company announcement identified to explain the surge.
● Spruce Biosciences shares have pushed sharply higher, finishing at $58.65, up 13.71%, a day after the company disclosed constructive regulatory news on its lead program.
● Scribe Therapeutics shares have risen to $37.25, up 9.14%, onVolumerunning about 2.5 times its recent average, extending a remarkable post-IPO run.
● Picard Medical shares have staged a dramatic rebound, most recently closing at $5.13, up 59.81%, on relativeVolumeof roughly 22 times normal, reversing a sharp mid-month slide that had dragged the stock toward $3.
● QT Imaging shares have advanced to close at $3.31, up 13.75%, on relativeVolumeof roughly 1.6 times its recent average, extending momentum built through a strong August of updates.
● Anbio Biotechnology shares have added to recent gains, closing near $7.90, up 16.01%, with relativeVolumeonly modestly elevated at around 1.48.
● Nutriband shares have surged to $5.11, up 9.51%, with relative turnover hitting 20.2 times normal on roughly 257,000 shares, an extraordinary spike for a company whose daily trading is usually sleepy.
Please wait processing your request...